ST张家界：2025年前三季度净利润约-2240万元

Group 1 - ST Zhangjiajie reported a revenue of approximately 337 million yuan for the first three quarters of 2025, representing a year-on-year increase of 8.51% [1] - The company experienced a net loss attributable to shareholders of approximately 22.4 million yuan, with a basic earnings per share loss of 0.06 yuan [1] - As of the report date, ST Zhangjiajie's market capitalization stands at 3.1 billion yuan [2] Group 2 - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion US dollars this year [2] - The secondary market for biopharmaceuticals is thriving, while the primary market is facing challenges in fundraising [2]